Previous DNA and RNA-driven molecular subtyping predicts EGFR expression in the classical subset of glioblastoma tumors and CD44 expression in mesenchymal tumors (Verhaak et al., 2010). The gene discussed is CD44; the disease is mesenchymal cell neoplasm.